| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | 0.058 | 0.06 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.066 | 0.07 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.063 | 0.07 |
| mRNA | AZD8055 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.07 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | -0.052 | 0.07 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | -0.056 | 0.07 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.056 | 0.07 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.057 | 0.07 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.091 | 0.07 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | -0.053 | 0.07 |